Loading...
•
Dec 31, 2019
Arrowhead Pharmaceuticals Q1 2020 Earnings Report
Reported first quarter fiscal year 2020 results, which included revenue of $29.45 million and a net loss of $2.67 million.
Key Takeaways
Arrowhead Pharmaceuticals reported a net loss of $2.67 million, or $0.03 per share, and revenue of $29.45 million for the fiscal first quarter ended December 31, 2019.
Began dosing patients and completed enrollment of the first sequential cohort in the AROAAT2002 study.
Reported interim multiple-dose results on two cardiometabolic candidates ARO-APOC3 and ARO-ANG3.
Completed regulatory submissions to begin Phase 1 studies of ARO-HSD and ARO-HIF2.
Improved the balance sheet and extended Arrowhead’s cash runway with a financing with gross proceeds of approximately $267 million.